ATRC News and Press, AtriCure Inc. From 11/01/22

AtriCure press release ( NASDAQ: ATRC ): Q3 GAAP EPS of -$0.27 misses by $0.02 . Revenue of $83.2M (+18.1% Y/Y) beats by $1.88M . 2022 Financial Guidance Full year 2022 revenue is projected to be approximately $328 million to $333 million vs $328.61M consen...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results. “We are proud to ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2022 financial results on ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education webcast at 2:00 p.m. Eastern T...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Morgan Stanley 20 th ...

AtriCure, Inc. (ATRC) Q2 2022 Earnings Conference Call August 2, 2022 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants ...

AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.32 misses by $0.03 . Revenue of $84.53M (+18.4% Y/Y) beats by $4.86M . Full year 2022 revenue is projected to be approximately $323 million to $333 million, reflecting growth of approximately 18% to 21...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a ...

Cryoport has done well to grow its top line in recent years and some bottom line figures have also fared well. Growth is expected to continue this year, but this doesn't make the company a wise investment. Shares look very expensive right now and are unlikely to offer material ups...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on...